NRD
PFE icon

Nebula Research & Development’s Pfizer PFE Stock Holding History

Nebula Research & Development’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-23,599
Closed -$683K – 1062
2024
Q3 		$683K Buy
23,599
+389
+2% +$11.3K 0.08% 451
2024
Q2 		$649K Sell
23,210
-1,768
-7% -$48.7K 0.11% 350
2024
Q1 		$693K Buy
24,978
+6,962
+39% +$193K 0.15% 251
2023
Q4 		$519K Buy
+18,016
New +$545K 0.16% 241

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nebula Research & Development's PFE Position: Q4 2024 in Review

Nebula Research & Development sold out of Pfizer (PFE) in Q4 2024, closing a stake of 23,599 shares — an estimated $683K sold.

Nebula Research & Development first reported a position in PFE in Q4 2023 and held it in 4 quarters. The position peaked at $693K in Q1 2024. 2,996 funds tracked by Wall St. Rank hold PFE as of Q4 2024.

  • Nebula Research & Development reported no remaining Pfizer position as of Q4 2024 after selling out during the quarter.
  • Nebula Research & Development sold 23,599 Pfizer shares in Q4 2024, an estimated $683K.
  • Nebula Research & Development first reported a position in Pfizer in Q4 2023 and held it in 4 quarters.
  • Nebula Research & Development's Pfizer position peaked at $693K in Q1 2024.
  • 2,996 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.

Based on Nebula Research & Development's 13F filing for Q4 2024, filed 14 Feb 2025.